H.M. PHARMA CONSULTANCY PRESENTS AT ADAPTIVE TRIALS 2009 CONGRESS AND PUBLISHES INVITED REVIEW ON RETINAL PATENTING

Vienna, December 22, 2009 – H.M. Pharma Consultancy's public activities in December 2009 included two highlights: Dr. Hermann Mucke's presentation at the Adaptive Trials 2009 conference in Brussels titled “Adaptive Clinical Designs: Understanding the Evolving Developer-Regulator Interface,” and the publication of the invited review paper, “Current drug patenting for retinal diseases: Beyond VEGF inhibitors” which will appear in the January 2010 print edition of the reputed journal IDrugs.

“This underscores how the community starts to recognize our dedication to continued innovation in clinical trials as well as in patent data management,” said H.M. Pharma Consultancy's founder and owner, Dr. Mucke. “Adaptive trial designs can speed early-stage drug development and save experimental animals. Patent informatics – clearly a neglected field when compared to the possibilities that exist for peer-reviewed papers – not only allow better prior art searches, but offer entirely new perspectives in life science knowledge management.”

similar news

 New Insight Pharma Report published - 19.07.2009 08:41

Links:

Click here for PubMed entry